Abstract
Purpose
Drug-eluting stents (DES) improve clinical and morphological long-term results compared to percutaneous transluminal angioplasty (PTA) with bailout bare metal stenting (BMS) in patients with critical limb ischemia (CLI) and infrapopliteal lesions (PADI trial). We performed a cost-effectiveness analysis of DES compared to PTA ± BMS in cooperation with Dutch health insurance company VGZ, using data from the PADI trial.
Materials and Methods
In the PADI trial, adults with CLI (Rutherford category ≥ 4) and infrapopliteal lesions were randomized to receive DES with paclitaxel or PTA ± BMS. Seventy-four limbs (73 patients) were treated with DES and 66 limbs (64 patients) with PTA ± BMS. The costs were calculated by using the mean costs per stent multiplied by the mean number of stents used per patient (€750 × 1.8 for DES vs €250 × 0.3 for PTA ± BMS). These costs were compared with the costs of major amputation (€16.000) and rehabilitation (first year €15.750, second year €7.375 and third year €3.600).
Results
The 5-year major amputation rate was lower in the DES group (19.3% vs 34.0% for PTA ± BMS; p = 0.091). In addition, the 5-year amputation-free survival and event-free survival were significantly higher in the DES group (31.8% vs 20.4%, p=0.043; and 26.2% vs 15.3%, p=0.041, respectively). After 1 year, the cost difference per patient between DES and PTA ± BMS is €1.679 in favor of DES and €2.694 after 3 years.
Conclusion
In our analysis, DES are cost-effective due to the higher hospital costs of amputation and rehabilitation in the PTA ± BMS group.
Level of Evidence
Level 1b, analysis based on clinically sensible costs and randomized controlled trial.
Similar content being viewed by others
References
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–67. https://doi.org/10.1016/j.jvs.2006.12.037.
Spreen MI, Gremmels H, Teraa M, Sprengers RW, Verhaar MC, van Eps RGS, et al. Diabetes is associated with decreased limb survival in patients with critical limb ischemia: pooled data from two randomized controlled trials. Diabetes Care. 2016;39(11):2058–64. https://doi.org/10.2337/dc16-0850.
Graziani L, Silvestro A, Bertone V, Manara E, Andreini R, Sigala A, et al. Vascular involvement in diabetic subjects with ischemic foot ulcer: a new morphologic categorization of disease severity. Eur J Vasc Endovasc Surg: Off J Eur Soc Vasc Surg. 2007;33(4):453–60. https://doi.org/10.1016/j.ejvs.2006.11.022.
Teraa M, Conte MS, Moll FL, Verhaar MC. Critical limb ischemia: current trends and future directions. J Am Heart Assoc. 2016;5(2):e002938. https://doi.org/10.1161/jaha.115.002938.
Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss L, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(14):1555–70. https://doi.org/10.1016/j.jacc.2013.01.004.
Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366(9501):1925–34. https://doi.org/10.1016/S0140-6736(05)67704-5.
Hicks CW, Najafian A, Farber A, Menard MT, Malas MB, Black JH, et al. Below-knee endovascular interventions have better outcomes compared to open bypass for patients with critical limb ischemia. Vasc Med. 2017;22(1):28–34. https://doi.org/10.1177/1358863X16676901.
Nehler MR, Coll JR, Hiatt WR, Regensteiner JG, Schnickel GT, Klenke WA, et al. Functional outcome in a contemporary series of major lower extremity amputations. J Vasc Surg. 2003;38(1):7–14.
Mustapha JA, Finton SM, Diaz-Sandoval LJ, Saab FA, Miller LE. Percutaneous transluminal angioplasty in patients with infrapopliteal arterial disease: systematic review and meta-analysis. Circ Cardiovasc Interv. 2016;9(5):e003468. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003468.
Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55(2):390–8. https://doi.org/10.1016/j.jvs.2011.07.099.
Falkowski A, Poncyljusz W, Wilk G, Szczerbo-Trojanowska M. The evaluation of primary stenting of sirolimus-eluting versus bare-metal stents in the treatment of atherosclerotic lesions of crural arteries. Eur Radiol. 2009;19(4):966–74. https://doi.org/10.1007/s00330-008-1225-1.
Siablis D, Kitrou PM, Spiliopoulos S, Katsanos K, Karnabatidis D. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7(9):1048–56. https://doi.org/10.1016/j.jcin.2014.04.015.
Rastan A, Brechtel K, Krankenberg H, Zahorsky R, Tepe G, Noory E, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol. 2012;60(7):587–91. https://doi.org/10.1016/j.jacc.2012.04.035.
Scheinert D, Katsanos K, Zeller T, Koppensteiner R, Commeau P, Bosiers M, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60(22):2290–5. https://doi.org/10.1016/j.jacc.2012.08.989.
Rastan A, Tepe G, Krankenberg H, Zahorsky R, Beschorner U, Noory E, et al. Sirolimus-eluting stents versus bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32(18):2274–81. https://doi.org/10.1093/eurheartj/ehr144.
Spreen MI, Martens JM, Hansen BE, Knippenberg B, Verhey E, van Dijk LC, et al. Percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia (PADI) trial. Circ Cardiovasc Interv. 2016;9(2):e002376. https://doi.org/10.1161/CIRCINTERVENTIONS.114.002376.
Spreen MI, Martens JM, Knippenberg B, van Dijk LC, de Vries JPM, Vos JA, et al. Long-term follow-up of the PADI trial: percutaneous transluminal angioplasty versus drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Am Heart Assoc. 2017;6(4):e004877. https://doi.org/10.1161/jaha.116.004877.
Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517–38.
Katsanos K, Karnabatidis D, Diamantopoulos A, Spiliopoulos S, Siablis D. Cost-effectiveness analysis of infrapopliteal drug-eluting stents. Cardiovasc Interv Radiol. 2013;36(1):90–7. https://doi.org/10.1007/s00270-012-0370-8.
Sridharan ND, Boitet A, Smith K, Noorbakhsh K, Avgerinos E, Eslami MH, et al. Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery. J Vasc Surg. 2018;67(1):343–52. https://doi.org/10.1016/j.jvs.2017.06.112.
Locham SS, Paracha N, Dakour-Aridi H, Nejim B, Rizwan M, Malas MB. comparison of the cost of drug-eluting stents versus bare metal stents in the treatment of critical limb ischemia in the United States. Ann Vasc Surg. 2019;55(55–62):e2. https://doi.org/10.1016/j.avsg.2018.05.051.
Secemsky EA, Kundi H, Weinberg I, Jaff MR, Krawisz A, Parikh SA, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019. https://doi.org/10.1001/jamacardio.2019.0325.
Secemsky EA, Kundi H, Weinberg I, Schermerhorn M, Beckman JA, Parikh SA, et al. Drug-eluting stent implantation and long-term survival following peripheral artery revascularization. J Am Coll Cardiol. 2019;73(20):2636–8. https://doi.org/10.1016/j.jacc.2019.02.020.
Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245. https://doi.org/10.1161/JAHA.118.011245.
Becker F, Robert-Ebadi H, Ricco JB, Setacci C, Cao P, de Donato G, et al. Chapter I: definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg: Off J Eur Soc Vasc Surg. 2011;42(Suppl 2):S4–12. https://doi.org/10.1016/S1078-5884(11)60009-9.
Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. J Vasc Surg. 2010;51(1):230–41. https://doi.org/10.1016/j.jvs.2009.08.073.
Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg. 1999;12(2):142–7.
Feiring AJ. Footnotes on critical limb ischemia. J Am Coll Cardiol. 2008;51(20):1975–6. https://doi.org/10.1016/j.jacc.2008.02.041.
Funding
This study was not supported by any funding.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
Hans van Overhagen is PI of the PADI trial, PI of the SAVAL trail and consultant of Boston Scientific. The remaining authors declare that they have no conflict of interest.
Informed Consent
For this type of study, formal consent is not required. For this type of study, informed consent is not required. For this type of study, consent for publication is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wakkie, T., Konijn, L.C.D., van Herpen, N.P.C. et al. Cost-Effectiveness of Drug-Eluting Stents for Infrapopliteal Lesions in Patients with Critical Limb Ischemia: The PADI Trial. Cardiovasc Intervent Radiol 43, 376–381 (2020). https://doi.org/10.1007/s00270-019-02385-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-019-02385-5